PubHawk
N Engl J Med February 2021 PMID 33626254

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.

Stephen K Brannan, Sharon Sawchak, Andrew C Miller, Jeffrey A Lieberman, Steven M Paul, Alan Breier

Full text PDF Download social card

Mentions

75
Peak: 33 in Feb 2021
across 6 sources since Feb 2021

Extended reach

198,109
potential audience

Total likes

581

Video views

27,372

Mentions per month

Feb 2021 – Jun 2025

Where it's discussed

  • X / Twitter57 posts
  • News9 articles
  • Facebook4 posts
  • YouTube2 videos
  • Blogs2 articles
  • Reddit1 posts

AI synopsis

What people are saying

The overall tone reflects strong support and keen interest, as users praise the novel approach of targeting muscarinic receptors, with comments like 'promising phase 2 results' and phrases such as 'finally this promising idea bears fruit.' The detailed discussions about side effects, such as cholinergic and anticholinergic events, and references to the study's significance demonstrate deep engagement and acknowledgment of potential clinical impact.

AgreementModerate agreement

Most discussions are positive, highlighting promising trial results and potential breakthroughs in schizophrenia treatment.

InterestHigh interest

Many posts express high interest, referencing the unique mechanism of action and implications for future therapies.

EngagementHigh engagement

Posts contain detailed commentary, including mentions of the study's methodology, side effects, and clinical relevance, indicating deep engagement.

ImpactHigh impact

The enthusiasm and emphasis on the trial's significance suggest these discussions view the findings as impactful for psychiatry and pharmacology.

Abstract in brief

  • * Conducted over 5 weeks with 182 patients, results indicated that those receiving xanomeline-trospium experienced a significantly greater reduction in schizophrenia symptoms, as measured by the PANSS score, compared to the placebo group.
  • * While the combination therapy showed improved effectiveness in several secondary measures, there were still some adverse events, although specific common adverse effects were not detailed in the text.
Read the full abstract

Top posts

Most liked on X and Bluesky
Aristotle Voineskos
@AVoineskos · X

Possible new treatment for people with #schizophrenia. New #RCT just out in @NEJM. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/ZlKe93zD2I

Feb 25, 2021 · 24 likes · 5 shares · 3,118 followers View post →
Luke Nakaji/中島 振一郎@バルサと島巡りと猫と精神医療
@Luke_629 · X

#統合失調症 に対するムスカリンM1/M4受容体刺激薬の第3相試験でプラセボに対する優位性が報告 FDA承認されれば、数十年ぶりの、本当の意味での新薬となります 第2相はNEJMで報告されています https://t.co/OWkLqzlndK 最初は認知症用に開発されていた経緯やコリン系副作用を抑える工夫も面白いです https://t.co/bgAKnh5eQD

Aug 8, 2022 · 17 likes · 5 shares · 2,282 followers View post →
Xavier Castells
@xccastells · X

Primer antipsicòtic que no actua sobre receptors dopaminèrgics ni serotoninèrgics. Caldrà estar atents. https://t.co/1FBGBnDtxP https://t.co/NDT7UwNyof

Feb 25, 2021 · 16 likes · 418 followers View post →
BryanRoth
@zenbrainest · X

Intriguing https://t.co/TrDjEajjZd

Mar 1, 2021 · 13 likes · 2 shares · 17,146 followers View post →
Prof.Dr.Mesut Cetin
@profmesutcetin · X

Şizofreni için yeni tedavi umudu mu? 5 haftalık bir çalışmada, xanomeline-trospium, PANSS toplam skorunda plaseboya göre daha büyük bir düşüşe neden oldu, ancak kolinerjik ve antikolinerjik yan etkilerle ilişkilendirildi. https://t.co/PcSJBdp1U5

Mar 9, 2021 · 9 likes · 1 share · 2,547 followers View post →
Saeed Farooq
@sfarooqlrh · X

Impressive results with combination of Muscarinic Cholinergic Receptor Agonist (xanomeline) and Peripheral Antagonist (Trospium) in treatment of Schizophrenia. You rarely see schizophrenia or psychiatry trials published in NEJM. My take https://t.co/ZjQLwHeUGW

Feb 26, 2021 · 6 likes · 1,910 followers View post →

All mentions

Mark Oldham
@MarkOldhamMD · X

@RealMilesBerger @saralahue @Orilieberman Sort of like this? https://t.co/iQcB03wrnq

Apr 26, 2023 · 2,300 followers View post →
Austin Lam
@austinaldenlam · X

https://t.co/eZHtwR3F2m

Apr 7, 2023 · 1,088 followers View post →
François Montastruc, MD, PhD
@montastrucf · X

2/ un candidat à rapprocher d'un autre agoniste M4/M1 la xanomeline avec l'essai de phase 2 dans la schizophrénie @NEJM https://t.co/JXSGkRVt2w

Dec 27, 2022 · 1,070 followers View post →
FHux
@huxley_f · X

The anti-cholinergic properties of low-potency first-generation anti-psychotics were often assumed to be adverse effects of the medication but might have just been the cost of one primary mechanism of action. https://t.co/Zku4ivGZYc

Nov 15, 2022 · 139 followers View post →
nko
@MKS2750 · X

RT @Luke_629: #統合失調症 に対するムスカリンM1/M4受容体刺激薬の第3相試験でプラセボに対する優位性が報告 FDA承認されれば、数十年ぶりの、本当の意味での新薬となります 第2相はNEJMで報告されています https://t.co/OWkLqzlndK…

Aug 9, 2022 · 5 shares · 170 followers View post →
ドラクロワン
@momofizz · X

RT @Luke_629: #統合失調症 に対するムスカリンM1/M4受容体刺激薬の第3相試験でプラセボに対する優位性が報告 FDA承認されれば、数十年ぶりの、本当の意味での新薬となります 第2相はNEJMで報告されています https://t.co/OWkLqzlndK…

Aug 9, 2022 · 5 shares · 115 followers View post →
Luke Nakaji/中島 振一郎@バルサと島巡りと猫と精神医療
@Luke_629 · X

RT @Luke_629: #統合失調症 に対するムスカリンM1/M4受容体刺激薬の第3相試験でプラセボに対する優位性が報告 FDA承認されれば、数十年ぶりの、本当の意味での新薬となります 第2相はNEJMで報告されています https://t.co/OWkLqzlndK…

Aug 9, 2022 · 5 shares · 2,282 followers View post →
T.Iiduka Welfare
@ti_Welfare · X

RT @Luke_629: #統合失調症 に対するムスカリンM1/M4受容体刺激薬の第3相試験でプラセボに対する優位性が報告 FDA承認されれば、数十年ぶりの、本当の意味での新薬となります 第2相はNEJMで報告されています https://t.co/OWkLqzlndK…

Aug 8, 2022 · 5 shares · 734 followers View post →
T.Iiduka Welfare
@ti_Welfare · X

RT @Luke_629: #統合失調症 に対するムスカリンM1/M4受容体刺激薬の第3相試験でプラセボに対する優位性が報告。承認されれば、数十年ぶりの、本当の意味での新薬となる。第2相はNEJMで報告→ https://t.co/OWkLqzlndK

Aug 8, 2022 · 1 share · 734 followers View post →
Veera Rajagopal 
@doctorveera · X

Phase-2 trial published last year. https://t.co/5rhUnI724f

Aug 8, 2022 · 1 like · 19,341 followers View post →
Luke Nakaji/中島 振一郎@バルサと島巡りと猫と精神医療
@Luke_629 · X

#統合失調症 に対するムスカリンM1/M4受容体刺激薬の第3相試験でプラセボに対する優位性が報告 FDA承認されれば、数十年ぶりの、本当の意味での新薬となります 第2相はNEJMで報告されています https://t.co/OWkLqzlndK 最初は認知症用に開発されていた経緯やコリン系副作用を抑える工夫も面白いです https://t.co/bgAKnh5eQD

Aug 8, 2022 · 17 likes · 5 shares · 2,282 followers View post →
Luke Nakaji/中島 振一郎@バルサと島巡りと猫と精神医療
@Luke_629 · X

#統合失調症 に対するムスカリンM1/M4受容体刺激薬の第3相試験でプラセボに対する優位性が報告。承認されれば、数十年ぶりの、本当の意味での新薬となる。第2相はNEJMで報告→ https://t.co/OWkLqzlndK https://t.co/bgAKnh5eQD

Aug 8, 2022 · 2 likes · 1 share · 2,282 followers View post →
Julio A. González G.
@jagonzalez21 · X

Un mecanismo de acción diferente al bloqueo dopaminérgico para el tratamiento de los síntomas psicóticos en pacientes esquizofrénicos: el agonismo de receptores muscarínicos. https://t.co/RtEw1GRvKg

Apr 8, 2021 · 433 followers View post →
Dr Kourosh Parvizi
@KouroshParvizi · X

“Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia” Really interesting paper here in the NEJM from Feb. Sig less psychosis (PANSS) + no ^ prevalence of side effects that usually are #1 reason for lack of compliance ! https://t.co/SM3b9XoT4z

Apr 8, 2021 · 2 likes · 109 followers View post →
salihnazli
@salihnazli4 · X

RT @profmesutcetin: Şizofreni için yeni tedavi umudu mu? 5 haftalık bir çalışmada, xanomeline-trospium, PANSS toplam skorunda plaseboya gör…

Apr 4, 2021 · 1 share · 2,735 followers View post →
Sameer Jauhar
@sameerjauhar · X

@joannamoncrieff @RADARprogramme We definitely nd better tx https://t.co/b0JuDet2Tx see what you think. Psychopharmacology is progressing

Mar 21, 2021 · 3 likes · 5,422 followers View post →
Prof.Dr.Mesut Cetin
@profmesutcetin · X

Şizofreni için yeni tedavi umudu mu? 5 haftalık bir çalışmada, xanomeline-trospium, PANSS toplam skorunda plaseboya göre daha büyük bir düşüşe neden oldu, ancak kolinerjik ve antikolinerjik yan etkilerle ilişkilendirildi. https://t.co/PcSJBdp1U5

Mar 9, 2021 · 9 likes · 1 share · 2,547 followers View post →
Ana Robles,MD,FAAN, #migrañard, #Liderencefaleas
@Anaroblesg · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/lGB3vimTCL

Mar 7, 2021 · 901 followers View post →
Progress
@progressnp · X

Promising phase 2 results for new antimuscarinic antipsychotic xanomeline-tropsium: https://t.co/Y96eI0ALut

Mar 6, 2021 · 201 followers View post →
@investigando
@rocatanho · X

Xanomeline-trospium, agonista muscarínico desprovisto del bloqueo dopaminérgico + antagonista muscarínico periférico, resultaría en mayor descenso sínt positivos y negativos en esquizofrenia, asoc con eventos adversos colinérgicos y anticolinérgicos https://t.co/0A06SyJVo1

Mar 4, 2021 · 395 followers View post →
Terry Hébert
@THebertMcGill · X

RT @zenbrainest: Intriguing https://t.co/TrDjEajjZd

Mar 1, 2021 · 2 shares · 2,191 followers View post →
Michael B. Fernando
@Mbfneuro · X

RT @zenbrainest: Intriguing https://t.co/TrDjEajjZd

Mar 1, 2021 · 2 shares · 640 followers View post →
BryanRoth
@zenbrainest · X

Intriguing https://t.co/TrDjEajjZd

Mar 1, 2021 · 13 likes · 2 shares · 17,146 followers View post →
Farmacia Madrid AP
@FarmaMadridAP · X

(NEJM) Agonista de receptores colinérgicos muscarínicos y antagonista periférico para la esquizofrenia https://t.co/Uq35r0Kg9A https://t.co/BZDxndFWUm

Mar 1, 2021 · 2 likes · 8,428 followers View post →
Krishan Maggon
@kkmaggon · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/muLU9bCMEM

Feb 28, 2021 · 999 followers View post →
pinacol
@pinacol · X

【RCT】統合失調症患者へのキサノメリンおよびトロスピウムの投与は、プラセボの投与と比較して、ベースラインから5週目時点での陽性・陰性症状評価尺度の点数をより減少させた。 #ペ読 https://t.co/dphFg2z2nG

Feb 27, 2021 · 1,676 followers View post →
Verstuyft Celine
@verstuyft4 · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/HAcRuYdBoD

Feb 27, 2021 · 235 followers View post →
Last Week in Medicine
@lastweekinmed · X

In a 5-week trial, xanomeline–trospium resulted in a greater decrease in the PANSS total score than placebo in people with #schizophrenia but was associated with cholinergic and anticholinergic adverse events. @NEJM https://t.co/TR8DOZmhVd

Feb 26, 2021 · 862 followers View post →
SEPSM
@SEPsiq · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/drAzHIISuw

Feb 26, 2021 · 2 likes · 1 share · 5,702 followers View post →
NINET Lab
@NinetLab · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/WxIyKswqzL

Feb 26, 2021 · 1 like · 1,269 followers View post →
Laure Rouch
@RouchLaure · X

RT @montastrucf: Modulation pharmacologique de l’activité muscarinique dans la schizophrenie, la notion de charge atropinique a de l’avenir…

Feb 26, 2021 · 1 share · 716 followers View post →
Saeed Farooq
@sfarooqlrh · X

Impressive results with combination of Muscarinic Cholinergic Receptor Agonist (xanomeline) and Peripheral Antagonist (Trospium) in treatment of Schizophrenia. You rarely see schizophrenia or psychiatry trials published in NEJM. My take https://t.co/ZjQLwHeUGW

Feb 26, 2021 · 6 likes · 1,910 followers View post →
Joe Pierre, MD
@psychunseen · X

oops, forgot to link article. https://t.co/86GhclY2nA

Feb 26, 2021 · 8,934 followers View post →
R. A Martin, Jr.
@DJROSTI · X

RT @GlobalMedEd: #Xanomeline and #trospium for treating schizophrenia. A truly innovative compound. https://t.co/nlyIUzM9o0 #nursepractitio…

Feb 26, 2021 · 2 shares · 5,832 followers View post →
Zoubir Djerada
@ZD79055334 · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/iqPRZucnE4

Feb 26, 2021 · 144 followers View post →
Luciano Sanchez
@lucmsanchez · X

RT @AVoineskos: Possible new treatment for people with #schizophrenia. New #RCT just out in @NEJM. Muscarinic Cholinergic Receptor Agonist…

Feb 26, 2021 · 5 shares · 276 followers View post →
Mental Health
@MentalHRetweet · X

RT @GlobalMedEd: #Xanomeline and #trospium for treating schizophrenia. A truly innovative compound. https://t.co/nlyIUzM9o0 #nursepractitio…

Feb 26, 2021 · 2 shares · 6,727 followers View post →
Giovanni Salum
@gsalumjr · X

RT @AVoineskos: Possible new treatment for people with #schizophrenia. New #RCT just out in @NEJM. Muscarinic Cholinergic Receptor Agonist…

Feb 26, 2021 · 5 shares · 538 followers View post →
François Montastruc, MD, PhD
@montastrucf · X

Modulation pharmacologique de l’activité muscarinique dans la schizophrenie, la notion de charge atropinique a de l’avenir

Feb 26, 2021 · 4 likes · 1 share · 1,070 followers View post →
Samuele Cortese
@CorteseSamuele · X

RT @AVoineskos: Possible new treatment for people with #schizophrenia. New #RCT just out in @NEJM. Muscarinic Cholinergic Receptor Agonist…

Feb 26, 2021 · 5 shares · 4,013 followers View post →
Benjamin Perry
@benjmnperry · X

RT @AVoineskos: Possible new treatment for people with #schizophrenia. New #RCT just out in @NEJM. Muscarinic Cholinergic Receptor Agonist…

Feb 26, 2021 · 5 shares · 1,135 followers View post →
George Dawson
@dawso007 · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/Y9p8MQz7AK

Feb 26, 2021 · 2 likes · 7,816 followers View post →
John McGrath
@John_J_McGrath · X

RT @AVoineskos: Possible new treatment for people with #schizophrenia. New #RCT just out in @NEJM. Muscarinic Cholinergic Receptor Agonist…

Feb 25, 2021 · 5 shares · 4,824 followers View post →
Aristotle Voineskos
@AVoineskos · X

Possible new treatment for people with #schizophrenia. New #RCT just out in @NEJM. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/ZlKe93zD2I

Feb 25, 2021 · 24 likes · 5 shares · 3,118 followers View post →
raj_psyc
@raj_psyc · X

New study Interesting 5-week double blind, phase 2 trial, xanomeline–trospium in patients with #Schizophrenia (n-182) showed significant decrease in the PANSS total score Vs placebo but was associated with cholinergic + anticholinergic side effects @NEJM https://t.co/X8ycTcXxoW

Feb 25, 2021 · 1 like · 12,580 followers View post →
ForensicPsyMD
@ForensicPsyMD · X

https://t.co/MIK7bpnKMA

Feb 25, 2021 · 362 followers View post →
Luke Nakaji/中島 振一郎@バルサと島巡りと猫と精神医療
@Luke_629 · X

https://t.co/OWkLqzlndK

Feb 25, 2021 · 2,282 followers View post →
john morley
@drjohnmorley · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/zRmyjuvxHe

Feb 25, 2021 · 8,286 followers View post →
Xavier Castells
@xccastells · X

Primer antipsicòtic que no actua sobre receptors dopaminèrgics ni serotoninèrgics. Caldrà estar atents. https://t.co/1FBGBnDtxP https://t.co/NDT7UwNyof

Feb 25, 2021 · 16 likes · 418 followers View post →
rincondesisifo
@rincondesisifo · X

(NEJM) Agonistas del receptor colinérgico y antagonistas periféricos en pac con esquizofrenia https://t.co/qkAVMyVj0P ECA #xanomelina #trospio https://t.co/NPVu0ShiiD

Feb 25, 2021 · 8,440 followers View post →
@investigando
@rocatanho · X

En pacientes con esquizofrenia xanomeline-trospium resultaría en un mayor descenso en la escala de síntomas positivos y negativos que placebo pero se asociaría con eventos adversos colinérgicos y anticolinérgicos https://t.co/FB4CVrmqtk

Feb 25, 2021 · 395 followers View post →
yoshiyuki nishio
@nishiokov · X

RT @Luke_629: Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for #Schizophrenia https://t.co/45mKIp2Byb @NEJM にムスカリン受容体刺…

Feb 24, 2021 · 1 share · 517 followers View post →
Luis Souza Motta
@lsouzamotta · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia | NEJM https://t.co/168QojLuhE

Feb 24, 2021 · 55 followers View post →
Rob Shaffer
@ShafferBiotech · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia $krtx | @NEJM https://t.co/XMwJDnE1gH

Feb 24, 2021 · 1,043 followers View post →
Larry Hardy
@Hardy508 · X

FINALLY this promising idea bears fruit. https://t.co/nhGpFigIsq

Feb 24, 2021 · 7 followers View post →
Luke Nakaji/中島 振一郎@バルサと島巡りと猫と精神医療
@Luke_629 · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for #Schizophrenia https://t.co/45mKIp2Byb @NEJM にムスカリン受容体刺激薬（＋末梢遮断薬）の統合失調症への効果が発表されました。 非ドーパミン薬の時代の到来でしょうか？再現が望まれます。

Feb 24, 2021 · 2 likes · 1 share · 2,282 followers View post →
Luke Nakaji/中島 振一郎@バルサと島巡りと猫と精神医療
@Luke_629 · X

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for #Schizophrenia | NEJM https://t.co/o9iVnwF17E

Feb 24, 2021 · 2,282 followers View post →
Schizophrenia Update: Navigating the Latest in Research and ...
News

DOI:10.1056/NEJMoa2017015 Brown DA (2019). Acetylcholine and cholinergic receptors. Brain Neurosci Adv, 3:2398212818820506. DOI:10.1177/2398212818820506 ...

Dec 14, 2025 View →
Addressing Positive, Negative, and Cognitive Symptoms of ...
News

DOI:10.1056/NEJMoa2017015 Brannan S, et al (2023). Safety and efficacy of KarXT in patients with schizophrenia in the randomized, double-blind, placebo ...

Dec 14, 2025 View →
Advancements in Non-Dopaminergic Treatments For Schizophrenia ...
News

DOI: 10.1056/NEJMoa2017015 [15] Shen JH, Zhao Y, Rosenzweig-Lipson S et al. A 6-week randomized, Japan Society for the Promotion of Science — http://dx.doi ...

Dec 14, 2025 View →
Jamapsychiatry Kaul 2024 Oi 240015 1721838763.4471 | PDF
News

2021;384(8):717-726. 2024, to fix an incorrect percentage in the Results. randomization codes, which were held by Signant doi:10.1056/NEJMoa2017015. Open ...

Dec 14, 2025 View →
Fpsyt 14 1321233 | PDF | Antipsychotic | Schizophrenia
News

cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. (2021) 384:717–26. doi: 10.1056/NEJMoa2017015 19. Weinberger DR.

Dec 14, 2025 View →
精神分裂症致力政策改革正当时（中文版） | PDF
News

Dysregulation of a specific NEJMoa2017015. PMID: 33626254; PMCID ... 10.1056/NEJMoa1911772. PMID: 32294346. 55 141. Hojlund M and Correll CU ...

Dec 14, 2025 View →
A New Era in Schizophrenia Care May Be Here | Psychology Today
Blogs

doi: 10.1056/NEJMoa2017015. Kaul, I., Sawchak, S., Claxton, A. et al. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled ...

Jun 12, 2025 View →
The novel schizophrenia drug showing renewed potential for better ...
News

doi:10.1056/nejmoa2017015. 9. Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline ...

Feb 5, 2025 View →
探索大腦的會談地圖- 成功研發思覺失調症藥物的生技公司"Karuna ...
Facebook

... 10.1056/NEJMoa2017015 《會談地圖》podcast 收聽平台Apple Podcast ➡️ https://reurl.cc/3NX9GR Google Podcast ➡️ https://reurl.cc/kVOgmG ...

Dec 27, 2023 View →
Clinical Overview: Updates in Pharmacologic Options for the ...
News

https://www.nejm.org/doi/full/10.1056/NEJMoa2017015. Dosing and administration of long-acting injectable antipsychotics for schizophrenia in ...

Jun 13, 2023 View →
Novel agents . About time . : r/Psychiatry
Reddit

... ), but results from this paper are pretty underwhelming. https://www.nejm.org/doi/full/10.1056/NEJMoa2017015 · WafflesCamus. • 4y ago.

Aug 19, 2021 View →
探索大腦的會談地圖- 一顆成功新藥的成本，主要在於研發漫長的過程 ...
Facebook

... 10.1056/NEJMoa2017015 《會談地圖》podcast 收聽平台Apple Podcast ➡️ https://reurl.cc/3NX9GR Google Podcast ➡️ https://reurl.cc/kVOgmG ...

Mar 28, 2021 View →
探索大腦的會談地圖- 新機轉作用在膽鹼系統的新型抗精神病藥物 ...
Facebook

... 10.1056/NEJMoa2017015 《會談地圖》podcast 收聽平台Apple Podcast ➡️ https://reurl.cc/3NX9GR Google Podcast ➡️ https://reurl.cc/kVOgmG ...

Mar 26, 2021 View →
探索大腦的會談地圖- Ep.04. 從臨床試驗分析生技新創的商業布局 ...
Facebook

... 10.1056/NEJMoa2017015 《會談地圖》podcast 收聽平台Apple Podcast ➡️ https://reurl.cc/3NX9GR Google Podcast ➡️ https://reurl.cc/kVOgmG ...

Mar 23, 2021 View →
精神分裂症新型治疗药物——毒蕈碱胆碱能受体激动剂和外周拮抗剂_ ...
News

《新英格兰医学杂志》(The New England Journal of Medicine)发表了Karuna Therapeutics公司的新型疗法KarXT的2期临床试验，结果令人振奋。

Mar 11, 2021 View →
Ann Robinson's research reviews—5 March 2021 - The BMJ
Blogs

doi:10.1056/NEJMoa2017015. Refined carbs are bad for rich and poor, especially for the overweight. In high income countries, a diet with a ...

Mar 5, 2021 View →